Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK ‐wide programme

and increased response, as well as NPM1 mut and use of LDAC (Tables S2 and S4). However, our findings from a real-world UK cohort demonstrate a rational means to successfully offer lower intensity chemotherapy to relapsed/refractory AML patients with early recourse to treatment discontinuation in those with a poor risk mutational profile or failure to respond within one to two treatment cycles.